Ethicon, Gmbh

Ortho-clinical Diagnostics, Inc

Millipore Corporation

Ortho Diagnostic Systems Inc.

Omrix Biopharmaceuticals Inc.

Robert W Van Holten

Dhanuraj Shetty

Olajompo Moloye-Olabisi

Degang Zhong

Jagdishchandra C Patel

Gerard H Llanos

Dwayne Lee Looney

Clifford A Dey

Xintian Ming

Jerome Riebman

Markus Bohn

Stephen M Autenrieth

Avner Brandes

Hans-Steffen Schacht

Ashley DeAnglis

Robert Vetrecin

Stephen C Yeadon

Elizabeth Vailhe

Gilbert J Quinton

George E Oulundsen, Jr

Ashley P Deanglis

Dhanuraj S Shetty

Robert B Vetrecin

The invention relates to a transparent, absorbent device for the dressing of wounds and insertion sites of percutaneous and drug delivery devices. The device provides 360 degree or complete circumferential protection of a wound or insertion site of a percutaneous or drug delivery device and comprises a hydrogel center and at least one absorbent material. The hydrogel center can optionally comprise a bioactive agent(s).

Dressing device

An adhesion inhibiting surgical barrier. The surgical barrier includes a wound-facing polymeric coating comprising an enteric polymer; and at least one flexible substrate, the at least one flexible substrate having at least one exterior surface, wherein the polymeric coating is applied to the at least one flexible substrate to substantially cover the at least one exterior surface thereof. A method of inhibiting the formation of adhesions in a patient who has undergone a surgical procedure and a method of repairing a gastric or duodenal perforation are also described herein.

Surgical barriers having adhesion inhibiting properties

An engagement head for engaging a porous substrate includes at least two pin sets, each pin set including a plurality of pins arranged in a plurality of parallel pin rows at a predetermined pin angle, wherein pins of immediately neighboring pin rows are arranged such that pin angles for the pins in a pin row are inversely symmetrical to pin angles for the pins in a neighboring pin row. The pins of a pin row move collectively in the same direction when a pin set is extended, which direction is determined by the pin angle of the pin row, whereby neighboring pin rows move in opposite longitudinal directions from one another when the pin set is extended. The pin sets may be extended and retracted in unison by a single actuation source.

Process and apparatus for coating a porous substrate with a coating liquid

The present invention is directed to a reinforced absorbable hemostat comprising at least one hemostatic agent in a single layer of nonwoven synthetic fabric having a mixture of compressed fiber staples of a polyglycolide/polylactide copolymer and a polydioxanone.

Reinforced absorbable synthetic matrix for hemostatic applications

The present invention is directed to a synthetic fabric comprising a multi-layered nonwoven fabric made from staples of a polyglycolide/polylactide copolymer, each layer having a different density. The multi-layer fabric can be used as a reinforced absorbable hemostat medical device.

Reinforced absorbable multi-layered fabric for hemostatic applications

A medically acceptable formulation comprising a diisocyanate terminated macromer or mixture thereof, and an oxidized cellulose.

Medically acceptable formulation of a diisocyanate terminated macromer for use as an internal adhesive or sealant

A hemostatic device comprising (i) a carrier comprising at least one component selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate; polyvinylacetate phthalate, cellulose acetate phthalate, acetaldehyde dimethylcellulose acetate, polymethacrylate-based polymers, and derivatives, salts, copolymers or combinations thereof; and (ii) thrombin.

Hemostatic device

The solvent-detergent (S/D) process is used to inactivate enveloped viruses in plasma products. While concentrations of 1.0% detergent and 0.3% tri-n-butyl phosphate solvent have been considered necessary for robust removal of viral activity, we show the effectiveness of solvent-detergent treatment after fractionation and nanofiltration of an immune gamma globulin preparation, which required significantly reduced concentrations of solvent and detergent. Reduced levels of solvent and detergent lead to greater efficiencies in their removal post-inactivation with the potential for greater yields and decreased processing costs.

Optimal placement of a robust solvent/detergent process post viral ultrafiltration of an immune gamma globulin

Methods for producing biological solutions such as immunoglobulins and in particular anti-D immunoglobulin substantially free of abnormal prion protein resulting therefrom. Specifically provided are methods for aggregation of prions and depth filtration of the biological solution to capture and remove abnormal and if desired, normal prion protein. The prion protein may then be eluted from the depth filter and filter washes and concentrated sufficient for detection at limits currently required by available assays.

Capture, concentration and quantitation of abnormal prion protein from biological fluids using depth filtration

Methods for producing immunoglobulins and in particular anti-D immunoglobulin substantially free of virus and product resulting therefrom. Specifically provided are methods for nanofiltration of the anti-D immunoglobulin in high ionic strength buffer and with excipient such as polysorbate 80. Additional steps include diafiltration to concentrate the anti-D protein and reduce the concentration of excipient present.

Growing community of inventors

Flemington, NJ, United States of America

Robert W Van Holten